Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer: Results from JMTO LC 0004

Isa, Shun‐ichi; Kawaguchi, Tomoya; Teramukai, Satoshi; Minato, Koichi; Ohsaki, Yoshinobu; Shibata, Kazuhiko; Yonei, Toshiro; Hayashibara, Kenji; Fukushima, Masanori; Kawahara, Mutsuto; Furuse, Kiyoyuki; Mack, Philip C.

doi:10.1097/jto.0b013e3181ae2844

Cited by 48 publications

(34 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chambers et al (7) suggested its prognostic value and other groups also supported this idea (22,25). Although the association between OPN and prognosis has been investigated over several years, no definitive conclusion has been drawn.…”

Section: Discussionmentioning

confidence: 68%

See 1 more Smart Citation

Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis

Zou

Wang

Liu

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Osteopontin (OPN) plays an important role in the progression and metastasis of cancer. However, the role of OPN as a prognostic factor in non-small-cell lung cancer (NSCLC) remains controversial. The aim of this study was to investigate the association between OPN expression and prognosis in patients with NSCLC using a meta-analysis. Based on PubMed, Ovid Medline, Embase, ISI, ScienceDirect and SpringerLink databases, related articles published prior to January, 2013 were collected. A meta-analysis was conducted to investigate the association of OPN expression with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC. Hazard ratio (HR) with 95% confidence interval (CI) was used to assess the strength of this association. A total of 6 studies, including 776 patients, were found to be eligible for the meta-analysis. No heterogeneity was observed in OS or PFS, whereas low OPN expression was found to be correlated with better OS (HR=0.57, 95% CI: 0.46-0.70) and PFS (HR=0.62, 95% CI: 0.49-0.77). This meta-analysis demonstrated an association of OPN with poor prognosis in NSCLC patients. However, prospective studies are required to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 68%

“…1). Three of those studies were conducted in America (21-23), two in Japan (24,25) and one in Italy (19). All the studies had a minimum follow-up of 2 years.…”

Section: Resultsmentioning

confidence: 99%

Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis

Zou

Wang

Liu

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…In their study the circulating osteopontin level is higher in stage III+IV than stage I+II. Latest research confirms that low osteopontin serum levels were significantly associated with a favorable prognosis in advanced NSCLC both in the Japanese patients (JMTO LC 0004) and the US population (SWOG study S0003 [23,24] . Our results suggested that osteopontin is critically involved in the aggressive progression of NSCLC.…”

Section: Discussionmentioning

confidence: 87%

Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer

Chen

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective: To investigate the relationship between postoperative metastasis and circulating levels of osteopontin in non-small cell lung cancer (NSCLC).Methods: The expression of osteopontin mRNA were detected with RT-PCR technique. The circulating levels of osteopontin were measured through ELASA in 46 NSCLC cases that had not been received any anti-cancer treatment at the time of sampling. The tissues from fifteen patients with benign pulmonary diseases were studied as control group.Results: The overall median mRNA expression level of osteopontin was approximately 70-fold higher in tumor tissues than in matched normal lung tissues (P<0.001). Over-expression of osteopontin mRNA was significantly associated with clinical stage (P=0.009). Advanced disease states had higher circulating level of osteopontin (stage I+II versus stage III+VI). In multivariate analysis, stage was the only independent factor influencing circulating levels of osteopontin. All patients were followed up for 12 months, 2 of the 46 patients with both osteopontin mRNA expression and elevated plasma osteopontin levels had local recurrence and 10 had distant metastasis. There was a significant difference in the osteopontin levels between metastasis group and non-metastasis group.Conclusion: Preoperative plasma levels of osteopontin are significantly associated with post-operative metastasis in advanced NSCLC.

show abstract

“…The prognostic relevance of elevated OPN plasma levels has been demonstrated in the chemotherapy (18,19) and surgery of NSCLC (20), and also for tumor volume. Furthermore, there is strong evidence in the literature that GTV is a potential prognostic factor in conformal RT of NSCLC (13)(14)(15)(16)21).…”

Section: Discussionmentioning

confidence: 99%

The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer

et al. 2016

View full text Add to dashboard Cite

Abstract. The prognostic quality of increased osteopontin (OPN) plasma levels has been demonstrated for the chemotherapy and surgery of lung cancer. There is also evidence in the literature that tumor volume impacts prognosis in definitive radiotherapy (RT) of (lung) cancer. We previously demonstrated that elevated plasma levels of OPN before, and increasing OPN plasma levels after RT significantly correlate with survival and outcome after curative-intent RT of non-small-cell lung cancer (NSCLC). Tumor volume was also associated with prognosis. The present prospective clinical study investigated the prognostic interrelation of OPN plasma levels and tumor volume and their changes in the radical RT of NSCLC. We evaluated a subset of patients (n=27) with inoperable, non-metastasized NSCLC of the previously published patient collective. Patients were treated with radical radiochemotherapy (2 Gy ad 66 Gy). OPN plasma concentrations were determined by ELISA before (t0), at the end (t1), and 4 weeks after RT (t2). GTV was delineated PET-and CT-correlated before RT (GTV1) and after 40 Gy (GTV2). The course of OPN during and after RT and the change of GTV during RT was monitored over time and correlated with prognosis. Median GTV2 after 40 Gy (63 ml) was significantly lower than pre-RT GTV1 (90 ml, P<0.0001). Median OPN before (t0), at the end of (t1) and four weeks after RT (t2) was 846, 777 and 624 ng/ml and not significantly different. GTV significantly declined by 39 ml during RT (P<0.0001) and OPN non-significantly decreased by 56 ng/ml during (t0 to t1) and by 54 ng/ml after RT (t1 to t2). No correlations were determined between absolute OPN and GTV values or their relative changes during RT. In univariate analysis, only GTV2 significantly predicted overall survival (OS, P=0.03). In multivariate analysis, both OPN t1 (P<0.001) and GTV2 (P= 0.001) remained significant predictors of OS. Relative OPN plasma level changes after (t1 to t2) and GTV changes during RT (GTV 1 to GTV 2) significantly predicted OS (P=0.02). The combination of absolute GTV values before RT (GTV1) and GTV changes during RT (GTV1 to 2) were significantly associated with OS in both uni-and multivariate analysis (P=0.03). The combination of absolute OPN plasma levels and their changes with GTV and its changes did not reach statistical significance. The lack of a significant correlation between OPN and GTV together with the finding that OPN and GTV remained independent predictors of survival outcome but were not associated with OS in combination supports the hypothesis that tumor volume (GTV) and OPN plasma levels (both their changes and absolute values) are not interrelated in terms of prognosis but do possess each parameter separately, a prognostic quality in the radical RT of NSCLC which justifies further prospective studies to validate these results.

show abstract

Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer: Results from JMTO LC 0004

Abstract: Consistent with the findings from SWOG 0003, low OPN serum levels were significantly associated with a favorable prognosis in the JMTO LC 0004. Additionally, high bFGF levels were associated with improved survival.

Cited by 48 publications

References 19 publications

Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis

Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis

Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer

The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer

Contact Info

Product

Resources

About